System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40129929 DOI: 10.3389/fcimb.2025.1562831

Gut microbiome is associated with radiotherapy response in lung cancer patients with brain metastases.

Front Cell Infect Microbiol 15:1562831

Authors: Fei Liang, Yichu Sun, Jing Yang, Ziqiang Shen, Guangfeng Wang, Jiangrui Zhu, Chong Zhou, Youyou Xia

Affiliations

  • Department of Radiation Oncology, the First People's Hospital of Lianyungang/ Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, China.
  • Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/ The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
  • Department of Radiation Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
  • Department of Radiation Oncology, the First People's Hospital of Lianyungang/ Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, China. Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/ The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.

Abstract

Purpose

To investigate the gut microbiome of lung cancer patients with brain metastases undergoing radiotherapy, identify key microorganisms associated with radiotherapy response, and evaluate their potential as biomarkers.

Methods and materials

This study enrolled 55 newly diagnosed lung cancer patients with brain metastases. Fecal samples were collected before radiotherapy and analyzed by 16S rRNA sequencing to assess the gut microbiome's composition and function. Patients were categorized into response (n=28) and non-response (n=27) groups based on treatment efficacy, and α-diversity, β-diversity, and functional pathways were compared between them. Linear Discriminant Analysis Effect Size was used to identify microbial features associated with treatment efficacy. Logistic regression analyses were performed to evaluate the predictive capacity of clinical and microbial factors for treatment outcomes.

Results

No significant difference in α-diversity was observed between the groups (P > 0.05), but β-diversity differed significantly (P = 0.036). Twelve characteristic microorganisms were identified in the response group, including and , and nine in the non-response group, such as and . Metabolic pathways associated with treatment response included ketone body metabolism and pathways related to amyotrophic lateral sclerosis. Multivariate analysis identified (odds ratio [OR] = 6.680, P = 0.004), (OR = 3.862, P = 0.014), C-reactive protein (OR = 1.054, P = 0.017), and systemic inflammation response index (OR = 1.367, P = 0.043) as independent predictors of radiotherapy response. The nomogram and microbiome models achieved area under the curve (AUC) values of 0.935 and 0.866, respectively, demonstrating excellent predictive performance. Decision curve analysis further confirmed these models provided significant net benefits across risk thresholds.

Conclusions

The composition and functional characteristics of the gut microbiome in lung cancer patients with brain metastases prior to radiotherapy are associated with therapeutic response and possess potential as predictive biomarkers. Further studies are warranted to validate these findings.

MeSH

Radiotherapy, Treatment Outcome, Lung, Brain, Neoplasms, Biomarkers, Cell Biology, Lung Neoplasms, Neoplasm Metastasis, Therapeutics, Gastrointestinal Microbiome